Screener
Tarsus Pharmaceuticals, Inc. TARS Restricted cash included in Prepaid expenses and other current assets
Restricted cash included in Prepaid expenses and other current assets at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCash.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 4:11 PM EST
- Fiscal year
- FY2025
- Accession
- 0001819790-26-000019
As of December 31, 2025 and 2024, the Company held $2.6 million of restricted cash as collateral for a letter of credit related to the Company’s new office space lease that was executed in December 2024 (see Note 9). Restricted cash that will be held for less than one year is reported in current assets and amounts that will be held for longer than one year are reported in non-current assets on the accompanying Balance Sheets.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s restricted cash included in prepaid expenses and other current assets?
- Tarsus Pharmaceuticals, Inc. (TARS) reported restricted cash included in prepaid expenses and other current assets of $2.6M in Q4 2025.
- What does restricted cash included in prepaid expenses and other current assets mean?
- Restricted cash included in Prepaid expenses and other current assets as reported by Tarsus Pharmaceuticals, Inc. Common Stock.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s restricted cash included in prepaid expenses and other current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude